Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer - Buzdar, AU; Ibrahim, NK; Francis, D (J Clin Oncol, 2005)
et al.